

TABLE OF CONTENTS

| | | |
|----------|---|------------|
| 1 | OVERVIEW OF THE IMPAACT NETWORK | 1-1 |
| 1.1 | Background of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network | 1-1 |
| 1.2 | IMPAACT Mission and Scientific Agenda..... | 1-2 |
| 1.3 | IMPAACT Network Organization | 1-4 |
| 1.4 | IMPAACT Operational Policies..... | 1-5 |
| 1.5 | Governmental Organizations Involved in IMPAACT Research | 1-6 |
| | | |
| 2 | NETWORK GROUPS | 2-1 |
| 2.1 | Network Leadership | 2-1 |
| 2.2 | Advisory Groups..... | 2-5 |
| 2.3 | Central Resources | 2-6 |
| 2.4 | Oversight Groups | 2-12 |
| 2.5 | Protocol Teams..... | 2-13 |
| 2.6 | Clinical Research Sites | 2-13 |
| | | |
| 3 | GOOD DOCUMENTATION PRACTICE | 3-1 |
| 3.1 | Introduction to Good Documentation Practices within the IMPAACT Network..... | 3-1 |
| 3.2 | General Guidelines for Document Creation, Review, and Management..... | 3-2 |
| | | |
| 4 | PROTOCOL TEAMS | 4-1 |
| 4.1 | Protocol Chair and Vice Chair | 4-1 |
| 4.2 | Protocol Team..... | 4-3 |
| 4.3 | Relationship of Protocol Team to IMPAACT Management Oversight Group (MOG) | 4-9 |
| 4.4 | Conflict Resolution within Protocol Teams | 4-9 |
| | | |
| 5 | COMMUNITY PARTICIPATION AND ENGAGEMENT IN THE IMPAACT NETWORK | 5-1 |
| 5.1 | Confidentiality | 5-1 |
| 5.2 | IMPAACT Community Advisory Board (ICAB)..... | 5-2 |
| 5.3 | ICAB Leadership Group (ILG)..... | 5-4 |
| 5.4 | IMPAACT Site Community Advisory Boards | 5-8 |

| | | |
|----------|--|------------|
| 5.5 | Community Input into the Protocol Development Process..... | 5-8 |
| 5.6 | Cross Network Collaborations and Community Partners..... | 5-9 |
| 6 | NETWORK MEETINGS AND COMMUNICATIONS | 6-1 |
| 6.1 | Meetings | 6-1 |
| 6.2 | Communication Mechanisms and Material Distribution | 6-2 |
| 6.3 | Release of Information to the Public..... | 6-4 |
| 7 | IMPAACT GENERAL POLICIES AND PROCEDURES: FUNDING, CONFLICT OF INTEREST, CERTIFICATE OF CONFIDENTIALITY, AND CLINICALTRIALS.GOV..... | 7-1 |
| 7.1 | IMPAACT Funding Procedures..... | 7-1 |
| 7.2 | Conflict of Interest and Financial Disclosure Policies | 7-3 |
| 7.3 | NIH Certificate of Confidentiality | 7-5 |
| 7.4 | Processes for Registration and Results Entry for IMPAACT Studies in ClinicalTrials.gov..... | 7-6 |
| 7.5 | Letters of Support | 7-9 |
| 8 | HUMAN SUBJECTS CONSIDERATIONS..... | 8-1 |
| 8.1 | Applicable US Federal Regulations and Guidelines | 8-1 |
| 8.2 | Training Requirements: Good Clinical Practice and Human Subjects Protection | 8-2 |
| 8.3 | IRB/EC Review and Approval | 8-4 |
| 8.4 | Other Regulatory Entities..... | 8-5 |
| 8.5 | Informed Consent and Assent | 8-6 |
| 8.6 | Special Populations | 8-10 |
| 8.7 | Confidentiality | 8-14 |
| 8.8 | Participant Costs for Study Participation..... | 8-14 |
| 8.9 | Participant Reimbursement for Study Participation | 8-15 |
| 8.10 | Access to HIV-Related Care..... | 8-15 |
| 8.11 | Local Reporting Requirements | 8-15 |
| 9 | PROTOCOL DEVELOPMENT AND MODIFICATIONS..... | 9-1 |
| 9.1 | Concept Development and Review..... | 9-3 |
| 9.2 | Protocol Development and Review..... | 9-6 |
| 9.3 | Protocol Modifications..... | 9-13 |

| | | |
|-----------|--|-------------|
| 9.4 | Co-Endorsed and Co-Development of Protocols and Other Networks' Studies | 9-19 |
| 10 | SITE SELECTION FOR IMPAACT STUDIES | 10-1 |
| 10.1 | Initial Site Selection for New Studies | 10-1 |
| 10.2 | Addition of Sites During Accrual of Ongoing Studies..... | 10-3 |
| 10.3 | Expansion Beyond the IMPAACT Network Affiliated Sites | 10-4 |
| 11 | STUDY-SPECIFIC PRE-IMPLEMENTATION ACTIVITIES: OPEN TO ACCRUAL AND SITE-SPECIFIC STUDY ACTIVATION..... | 11-1 |
| 11.1 | Study Open to Accrual Requirements..... | 11-2 |
| 11.2 | Site-Specific Study Activation | 11-10 |
| 12 | STUDY IMPLEMENTATION | 12-1 |
| 12.1 | Participant Accrual..... | 12-1 |
| 12.2 | Follow-Up Visits | 12-3 |
| 12.3 | Data Collection | 12-6 |
| 12.4 | Study Team Communications..... | 12-10 |
| 12.5 | Protocol Deviations..... | 12-17 |
| 13 | STUDY OVERSIGHT | 13-1 |
| 13.1 | On-Site Clinical Quality Management..... | 13-1 |
| 13.2 | Clinical Site Monitoring | 13-2 |
| 13.3 | Protocol Team Monitoring..... | 13-2 |
| 13.4 | IMPAACT Leadership Oversight..... | 13-3 |
| 13.5 | IMPAACT Study Monitoring Committee Review | 13-4 |
| 13.6 | Sponsor Oversight..... | 13-11 |
| 13.7 | IMPAACT Network Issue Escalation..... | 13-11 |
| 13.8 | Data and Safety Monitoring Board Reviews | 13-12 |
| 14 | SITE STUDY-SPECIFIC CLOSE-OUT..... | 14-1 |
| 14.1 | Overview, Key Principles, and Definitions | 14-1 |
| 14.2 | Timeline for Study Close-Out..... | 14-2 |

| | | |
|-----------|--|-------------|
| 14.3 | Study Close-Out Communications and Considerations for Sites..... | 14-6 |
| 15 | ANCILLARY STUDIES, INVESTIGATIONS, AND ACCESS TO STUDY DATA..... | 15-1 |
| 15.1 | Scope and Definitions..... | 15-1 |
| 15.2 | Responsibilities and Procedures for Development and Review of Ancillary Studies | 15-3 |
| | Development and Submission | 15-3 |
| 15.3 | Special Considerations for Proposals Requiring Genetic Analyses..... | 15-6 |
| 15.4 | Specimen and Data Usage Agreements..... | 15-7 |
| 15.5 | Responsibilities and Procedures for Completion of Ancillary Studies..... | 15-8 |
| 15.6 | Publications Resulting from Data Requests..... | 15-9 |
| 15.7 | Procedures for Access to Study Data During Trial Conduct and After Trial Completion..... | 15-9 |
| 16 | TRAINING FOR SITE KEY PERSONNEL AND OTHER SITE AND LABORATORY STAFF..... | 16-1 |
| 16.1 | Human Subjects Protection (HSP) and Good Clinical Practice (GCP) Training | 16-3 |
| 16.2 | Laboratory Related Training | 16-3 |
| 16.3 | Data Management Training | 16-4 |
| 16.4 | Research Ethics Training for Community Representatives..... | 16-5 |
| 16.5 | Study-Specific Training..... | 16-5 |
| 16.6 | Documenting Training..... | 16-10 |
| 17 | LABORATORY CONSIDERATIONS..... | 17-1 |
| 17.1 | Network Laboratory Center..... | 17-1 |
| 17.2 | IMPAACT Laboratories..... | 17-5 |
| 17.3 | Protocol-Specified Testing..... | 17-6 |
| 17.4 | IMPAACT Laboratory Network Requirements: US Laboratories | 17-6 |
| 17.5 | IMPAACT Laboratory Network Requirements: Non-US Laboratories..... | 17-7 |
| 17.6 | Laboratory Data Management System (LDMS)..... | 17-13 |
| 17.7 | Data Corrections..... | 17-13 |
| 17.8 | External Quality Assurance (EQA) Participation and Proficiency Testing Providers..... | 17-14 |
| 17.9 | Testing Backup Plans | 17-14 |
| 17.10 | Instrument and Method Validation | 17-15 |
| 17.11 | Management and Testing Plans | 17-16 |
| 17.12 | Shipping Capabilities | 17-17 |

| | | |
|-----------|---|-------------|
| 17.13 | Specimen Shipping..... | 17-17 |
| 17.14 | Specimen Archive and Destruction..... | 17-18 |
| 17.15 | National Approval Requirements and Material Transfer Agreements..... | 17-19 |
| 17.16 | IMPAACT Quality Assessment Monitoring | 17-20 |
| 17.17 | Introduction of Novel/Non-Standard Analytes into IMPAACT Studies | 17-20 |
| 17.18 | Changes in Laboratory Personnel | 17-23 |
| 17.19 | Laboratory Relocation..... | 17-23 |
| 17.20 | Additional Resources..... | 17-24 |
| 18 | NETWORK EVALUATION | 18-1 |
| 18.1 | Network Evaluation Plan and Performance Measures..... | 18-2 |
| 18.2 | Performance Criteria for IMPAACT-affiliated NIAID-funded Clinical Research Sites..... | 18-3 |
| 18.3 | Overall Network Productivity..... | 18-7 |
| 18.4 | Outcomes and Actions..... | 18-7 |
| 19 | DATA ANALYSIS AND PUBLICATIONS PROCEDURES..... | 19-1 |
| 19.1 | Overview, Key Principles, and Definitions | 19-1 |
| 19.2 | Key Responsibilities..... | 19-5 |
| 19.3 | Preparation, Review, and Completion of Analyses..... | 19-6 |
| 19.4 | Development and Review of Publications | 19-11 |
| 19.5 | Tracking of Manuscript Preparation..... | 19-19 |
| 19.6 | IMPAACT Publication Review Process..... | 19-19 |
| 19.7 | Journal Submission | 19-21 |
| 19.8 | Conference Submission..... | 19-21 |
| 19.9 | Authorship..... | 19-22 |
| 19.10 | Acknowledgements..... | 19-24 |
| 19.11 | Public Access Policy..... | 19-24 |
| 19.12 | Communications Plans and Dissemination of Study Results..... | 19-25 |
| 19.13 | Publication Costs..... | 19-27 |
| 19.14 | Concluding a Study..... | 19-27 |

| | | |
|-------------------|---------------------------------------|----------|
| APPENDIX I | UNBLINDING PROCEDURES | 1 |
| I.1 | Purpose | 1 |
| I.2 | Scope | 1 |
| I.3 | Definitions | 1 |
| I.4 | Roles and Responsibilities | 2 |
| I.5 | Reasons and Guidelines for Unblinding | 5 |
| I.6 | Procedures | 9 |
| I.7 | References | 10 |
| I.8 | Questions | 10 |